Valore202020212022202320242025TTMSpese di vendita, generali e amministrative68.84 M97.59 M106.9 M121 M142.79 M166.99 M166.99 MRicerca e sviluppo13.02 M16.29 M19.94 M21.04 M24.8 M27.56 M27.56 MReddito operativo2.37 M-7.85 M-17.06 M-6.46 M4.52 M11.04 M11.04 MProventi non operativi, Totale672 K272 K1.07 M4.1 M5.99 M6.33 M6.33 MOneri finanziari, al netto degli interessi capitalizzati13 K4 000366 K600 K614 K630 K630 KProventi non operativi, esclusi gli oneri finanziari665 K216 K609 K3.43 M5.18 M5.75 M5.75 MEntrate/uscite straordinarie-6 00052 K95 K64 K195 K-44 K-44 KUtile al lordo delle imposte3.04 M-7.58 M-15.99 M-2.37 M10.51 M17.38 M10.18 MQuota di utile———————Imposte180 K-111 K721 K814 K148 K859 K—Interessi di minoranza———————Altri proventi/oneri al netto delle imposte—-7 000-22 K-39 K-43 K-13 K-13 KUtile netto al lordo delle attività cessate2.86 M-7.47 M-16.71 M-3.18 M10.36 M16.52 M16.52 MAttività cessate———————Utile netto2.86 M-7.47 M-16.71 M-3.18 M10.36 M16.52 M16.52 MRegolazione della diluizione———————Dividendi privilegiati———————Utile netto diluito attribuibile agli azionisti ordinari2.86 M-7.47 M-16.71 M-3.18 M10.36 M16.52 M16.52 MUtile base per azione (EPS base)0.06-0.16-0.35-0.070.210.330.33Utile diluito per azione (EPS diluito)0.06-0.16-0.35-0.070.20.320.32Numero medio di azioni ordinarie in circolazione45.22 M46.47 M47.13 M47.59 M48.85 M50.34 M201.1 MAzioni diluite in circolazione47.28 M46.47 M47.13 M47.59 M51.68 M52.15 M204.33 MEBITDA4.75 M-4.85 M-13.08 M-1.83 M10.02 M22.59 M22.59 MEBIT2.37 M-7.85 M-17.06 M-6.46 M4.52 M11.04 M11.04 MCosto del fatturato39.95 M50.16 M54.58 M61.94 M65.12 M70.66 M70.66 MAltri costi del venduto—————1.04 M—Ammortamento e svalutazione (liquidità)2.38 M3 M3.98 M4.63 M5.5 M11.54 M11.54 M
Vericel Corporation
Vericel Corporation is a publicly traded American biopharmaceutical company which was known prior to October 2014 as Aastrom Bio. Aastrom Bio was formed in 1989 in Ann Arbor, Michigan.
In the spring of 2014, Aastrom Bio acquired Sanofi's cell therapy and regenerative medicine business which Sanofi had acquired when purchasing Genzyme in 2011. This transformed Aastrom in several ways: it increased the employee count by 8-fold and provided a revenue stream and products to market, which it had not had before.
In October 2014, the company changed its name from Aastrom Bio to Vericel and relocated its headquarters from Ann Arbor, Michigan to Cambridge, Massachusetts.